CPDC has made a $650,000 seed investment in RadioSyn, a McMaster University startup developing a miniaturized automated radiopharmaceutical synthesis platform. RadioSyn delivers a shielded, state-of-the-art synthesizer that eliminates traditional production barriers and complexity. Their automated synthesis technology platform addresses critical limitations in conventional diagnostic and therapeutic workflows by standardizing and streamlining radioimmunoconjugate and radiopharmaceutical manufacturing.   For more information, visit www.radiosyn.com